Mary‐Ellen Taplin
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 0.2%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
-
- Prostate Cancer Treatment and Research 111
- Prostate Cancer Diagnosis and Treatment 33
-
- Cancer, Lipids, and Metabolism 16
- Cancer Genomics and Diagnostics 8
- Co-authors
- Steven P. Balk (20 shared papers)Howard I. Scher (9 shared papers)Glenn J. Bubley (20 shared papers)Mohammad Hirmand (5 shared papers)Lynn Seely (2 shared papers)Karim S. Fizazi (5 shared papers)Fred Saad (5 shared papers)Johann Sebastian De Bono (5 shared papers)
- Journals
- Clinical Cancer Research (11 papers)Cancer (11 papers)Journal of Clinical Oncology (10 papers)The Prostate (9 papers)The Journal of Urology (9 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Mary‐Ellen Taplin
156 papers receiving 18.4k citations
Mary‐Ellen Taplin's Hit Papers
Peers
Comparison fields: 5 of 126
- Pulmonary and Respiratory Medicine 13.2k
- Cancer Research 4.3k
- Oncology 3.6k
- Endocrinology, Diabetes and Metabolism 2.0k
- Radiology, Nuclear Medicine and Imaging 1.9k
Countries citing papers authored by Mary‐Ellen Taplin
This map shows the geographic impact of Mary‐Ellen Taplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary‐Ellen Taplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary‐Ellen Taplin more than expected).
Fields of papers citing papers by Mary‐Ellen Taplin
This network shows the impact of papers produced by Mary‐Ellen Taplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary‐Ellen Taplin. The network helps show where Mary‐Ellen Taplin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary‐Ellen Taplin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 163 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3725 |
| 2 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Hit paper breakdown → | 2014 | 2453 |
| 3 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer Hit paper breakdown → | 2016 | 1335 |
| 4 | Genomic correlates of clinical outcome in advanced prostate cancer Hit paper breakdown → | 2019 | 1036 |
| 5 | Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer Hit paper breakdown → | 1995 | 1035 |
| 6 | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Hit paper breakdown → | 2010 | 882 |
| 7 | Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors Hit paper breakdown → | 2017 | 735 |
| 8 | The long tail of oncogenic drivers in prostate cancer Hit paper breakdown → | 2018 | 649 |
| 9 | Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. | 1999 | 497 |
| 10 | Integrative Clinical Genomics of Advanced Prostate Cancer Hit paper breakdown → | 2015 | 461 |
| 11 | Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline Hit paper breakdown → | 2007 | 448 |
| 12 | 2003 | 330 | |
| 13 | 2003 | 310 | |
| 14 | 2018 | 280 | |
| 15 | 2010 | 201 | |
| 16 | 2018 | 180 | |
| 17 | 2007 | 161 | |
| 18 | 2018 | 151 | |
| 19 | 2021 | 127 | |
| 20 | Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 Hit paper breakdown → | 2023 | 125 |
About Mary‐Ellen Taplin
Mary‐Ellen Taplin is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism, having authored 163 papers that have together received 18.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (111 papers), Prostate Cancer Diagnosis and Treatment (33 papers), Radiopharmaceutical Chemistry and Applications (16 papers), Cancer, Lipids, and Metabolism (16 papers), Hormonal and reproductive studies (14 papers), Cancer Genomics and Diagnostics (8 papers), PARP inhibition in cancer therapy (5 papers) and Bone health and treatments (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (13.2k citations), Cancer Research (4.3k citations), Oncology (3.6k citations), Endocrinology, Diabetes and Metabolism (2.0k citations) and Radiology, Nuclear Medicine and Imaging (1.9k citations). Mary‐Ellen Taplin has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Steven P. Balk, Howard I. Scher, Glenn J. Bubley, Mohammad Hirmand, Lynn Seely, Karim S. Fizazi, Fred Saad, Johann Sebastian De Bono, Andrew J. Armstrong and Cora Nanette Sternberg. Their work appears in journals such as Clinical Cancer Research, Cancer, Journal of Clinical Oncology, The Prostate and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.